Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,424
archived clinical trials in
Cognitive Studies

Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Radiant Research
2107
mi
from 43215
Santa Rosa, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Radiant Research
2107
mi
from 43215
Santa Rosa, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Research Center for Clinical Studies, Inc.
510
mi
from 43215
Norwalk, CT
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Research Center for Clinical Studies, Inc.
510
mi
from 43215
Norwalk, CT
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Chase Medical Research, LLC
532
mi
from 43215
Waterbury, CT
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Chase Medical Research, LLC
532
mi
from 43215
Waterbury, CT
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Brain Matters Research
948
mi
from 43215
Delray Beach, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Brain Matters Research
948
mi
from 43215
Delray Beach, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
MD Clinical
980
mi
from 43215
Hallandale Beach, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
MD Clinical
980
mi
from 43215
Hallandale Beach, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Galiz Research
989
mi
from 43215
Miami Springs, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Galiz Research
989
mi
from 43215
Miami Springs, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Renstar Medical Research
746
mi
from 43215
Ocala, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Renstar Medical Research
746
mi
from 43215
Ocala, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Compass Research LLC
795
mi
from 43215
Orlando, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Compass Research LLC
795
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Princeton Medical Institute
442
mi
from 43215
Princeton, NJ
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Princeton Medical Institute
442
mi
from 43215
Princeton, NJ
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Memory Enhancement Center Of Nj, Inc.
467
mi
from 43215
Toms River, NJ
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Memory Enhancement Center Of Nj, Inc.
467
mi
from 43215
Toms River, NJ
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Brooklyn Medical Institute
477
mi
from 43215
Brooklyn, NY
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Brooklyn Medical Institute
477
mi
from 43215
Brooklyn, NY
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Advanced Bio-Behavioral Sciences, Inc
489
mi
from 43215
Elmsford, NY
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Advanced Bio-Behavioral Sciences, Inc
489
mi
from 43215
Elmsford, NY
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
University of Rochester Medical Center at MCH
355
mi
from 43215
Rochester, NY
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
University of Rochester Medical Center at MCH
355
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Summit Research Network
2028
mi
from 43215
Portland, OR
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Summit Research Network
2028
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Grayline Clinical Drug Trials
951
mi
from 43215
Wichita Falls, TX
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Grayline Clinical Drug Trials
951
mi
from 43215
Wichita Falls, TX
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
The Memory Clinic
546
mi
from 43215
Bennington, VT
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
The Memory Clinic
546
mi
from 43215
Bennington, VT
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
The University of California Irvine
1958
mi
from 43215
Orange, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
The University of California Irvine
1958
mi
from 43215
Orange, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Meridien Research
789
mi
from 43215
Brooksville, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Meridien Research
789
mi
from 43215
Brooksville, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Social Psychiatry Research Institute
479
mi
from 43215
Brooklyn, NY
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Social Psychiatry Research Institute
479
mi
from 43215
Brooklyn, NY
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Columbus Research and Wellness Institute
525
mi
from 43215
Columbus, OH
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Columbus Research and Wellness Institute
525
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
FutureSearch Trials of Dallas, LP
905
mi
from 43215
Dallas, TX
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
FutureSearch Trials of Dallas, LP
905
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
The Center for Excellence in Aging and Geriatric Health
389
mi
from 43215
Williamsburg, VA
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
The Center for Excellence in Aging and Geriatric Health
389
mi
from 43215
Williamsburg, VA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Clinical Site 1
mi
from 43215
Bucharest,
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Clinical Site 1
mi
from 43215
Bucharest,
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Intergrated Medical and Behavioral Associates
1970
mi
from 43215
Glendale, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Intergrated Medical and Behavioral Associates
1970
mi
from 43215
Glendale, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Excell Research, Inc.
1944
mi
from 43215
Oceanside, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Excell Research, Inc.
1944
mi
from 43215
Oceanside, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
University of California, San Diego
1926
mi
from 43215
San Diego, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
University of California, San Diego
1926
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Affiliated Research Institute
1948
mi
from 43215
San Diego, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Affiliated Research Institute
1948
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Schuster Medical Research Institute
1981
mi
from 43215
Sherman Oaks, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Schuster Medical Research Institute
1981
mi
from 43215
Sherman Oaks, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Scientific Clinical Research
985
mi
from 43215
North Miami, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Scientific Clinical Research
985
mi
from 43215
North Miami, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Uptown Research Institute, Llc
274
mi
from 43215
Chicago, IL
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Uptown Research Institute, Llc
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Alexian Brothers Behavioral Health
303
mi
from 43215
Hoffman Estates, IL
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Alexian Brothers Behavioral Health
303
mi
from 43215
Hoffman Estates, IL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
CBH Health LLC
318
mi
from 43215
Rockville, MD
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
CBH Health LLC
318
mi
from 43215
Rockville, MD
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
CRI Worldwide, LLC
430
mi
from 43215
Willingboro, NJ
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
CRI Worldwide, LLC
430
mi
from 43215
Willingboro, NJ
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Carolina Clinical Trials, Inc.
519
mi
from 43215
Charleston, SC
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Carolina Clinical Trials, Inc.
519
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Vanderbilt Psychiatric Hospital
335
mi
from 43215
Nashville, TN
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Vanderbilt Psychiatric Hospital
335
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
FutureSearch Clinical Trials LP
1063
mi
from 43215
Austin, TX
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
FutureSearch Clinical Trials LP
1063
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
InSite Clinical Research LLC
921
mi
from 43215
DeSoto, TX
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
InSite Clinical Research LLC
921
mi
from 43215
DeSoto, TX
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
4598
mi
from 43215
Arkhangelsk,
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
4598
mi
from 43215
Arkhangelsk,
Click here to add this to my saved trials
Anticoagulation in AF Ablation and Effects on Neurocognitive Function
Uninterrupted Versus Interrupted Anticoagulation in Atrial Fibrillation Ablation - Cerebral Thromboemboli and Neurocognitive Performance
Status: Enrolling
Updated:  4/21/2014
University of California - San Francisco
2109
mi
from 43215
San Francisco, CA
Anticoagulation in AF Ablation and Effects on Neurocognitive Function
Uninterrupted Versus Interrupted Anticoagulation in Atrial Fibrillation Ablation - Cerebral Thromboemboli and Neurocognitive Performance
Status: Enrolling
Updated: 4/21/2014
University of California - San Francisco
2109
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Whole Coffee Fruit Concentrate Pilot Study 1
Effects of Whole Coffee Fruit Concentrate On Cognition and Mood In Healthy Adults: A Pilot Clinical Study
Status: Enrolling
Updated:  5/19/2014
UCLA Semel Institute
1982
mi
from 43215
Los Angeles, CA
Whole Coffee Fruit Concentrate Pilot Study 1
Effects of Whole Coffee Fruit Concentrate On Cognition and Mood In Healthy Adults: A Pilot Clinical Study
Status: Enrolling
Updated: 5/19/2014
UCLA Semel Institute
1982
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Status: Enrolling
Updated:  6/5/2014
Oregon Health and Science University
2026
mi
from 43215
Portland, OR
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Status: Enrolling
Updated: 6/5/2014
Oregon Health and Science University
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Effect of Medium Chain Triglyceride Oil Supplementation in Mild Cognitive Impairment
Effect of Medium Chain Triglyceride Oil Supplementation in Mild Cognitive Impairment
Status: Enrolling
Updated:  6/6/2014
Pennington Biomedical Research Center
803
mi
from 43215
Baton Rouge, LA
Effect of Medium Chain Triglyceride Oil Supplementation in Mild Cognitive Impairment
Effect of Medium Chain Triglyceride Oil Supplementation in Mild Cognitive Impairment
Status: Enrolling
Updated: 6/6/2014
Pennington Biomedical Research Center
803
mi
from 43215
Baton Rouge, LA
Click here to add this to my saved trials
Walking Interventions, Cognitive Remediation and Mild Cognitive Impairment
Walking Interventions, Cognitive Remediation and Mild Cognitive Impairment
Status: Enrolling
Updated:  6/6/2014
Pennington Biomedical Research Center
803
mi
from 43215
Baton Rouge, LA
Walking Interventions, Cognitive Remediation and Mild Cognitive Impairment
Walking Interventions, Cognitive Remediation and Mild Cognitive Impairment
Status: Enrolling
Updated: 6/6/2014
Pennington Biomedical Research Center
803
mi
from 43215
Baton Rouge, LA
Click here to add this to my saved trials
Effect of Phytochemicals on Aspects of Cognitive Performance
Effects of Phytochemicals on Aspects of Cognitive Performance
Status: Enrolling
Updated:  6/17/2014
Univerysity of Georgia
415
mi
from 43215
Athens, GA
Effect of Phytochemicals on Aspects of Cognitive Performance
Effects of Phytochemicals on Aspects of Cognitive Performance
Status: Enrolling
Updated: 6/17/2014
Univerysity of Georgia
415
mi
from 43215
Athens, GA
Click here to add this to my saved trials
On-line Treatment for Conduct Problems
Status: Enrolling
Updated:  6/18/2014
Yale Parenting Center
537
mi
from 43215
New Haven, CT
On-line Treatment for Conduct Problems
Status: Enrolling
Updated: 6/18/2014
Yale Parenting Center
537
mi
from 43215
New Haven, CT
Click here to add this to my saved trials
Methylphenidate Treatment of Attention Deficits in Epilepsy
Methylphenidate Treatment of Attentional and Cognitive Deficits in Epilepsy
Status: Enrolling
Updated:  7/9/2014
Stanford University
2100
mi
from 43215
Palo Alto, CA
Methylphenidate Treatment of Attention Deficits in Epilepsy
Methylphenidate Treatment of Attentional and Cognitive Deficits in Epilepsy
Status: Enrolling
Updated: 7/9/2014
Stanford University
2100
mi
from 43215
Palo Alto, CA
Click here to add this to my saved trials
Virtual Reality Based Balance Training in People With Mild Cognitive Impairment
Virtual Reality Based Balance Training in People With Mild Cognitive Impairment: A Pilot Study
Status: Enrolling
Updated:  8/11/2014
Banner Sun Health Research Institute
1669
mi
from 43215
Sun City, AZ
Virtual Reality Based Balance Training in People With Mild Cognitive Impairment
Virtual Reality Based Balance Training in People With Mild Cognitive Impairment: A Pilot Study
Status: Enrolling
Updated: 8/11/2014
Banner Sun Health Research Institute
1669
mi
from 43215
Sun City, AZ
Click here to add this to my saved trials
Effect of Blueberries on Cognition and Body Composition in Elderly With Mild Cognitive Decline
The Effect of Blueberry Consumption on Cognition and Body Composition in Elderly Who Are Experiencing Mild Cognitive Decline
Status: Enrolling
Updated:  9/6/2014
Nutrition Research Institute
334
mi
from 43215
Kannapolis, NC
Effect of Blueberries on Cognition and Body Composition in Elderly With Mild Cognitive Decline
The Effect of Blueberry Consumption on Cognition and Body Composition in Elderly Who Are Experiencing Mild Cognitive Decline
Status: Enrolling
Updated: 9/6/2014
Nutrition Research Institute
334
mi
from 43215
Kannapolis, NC
Click here to add this to my saved trials
Blood/Interstitial Glucose Measurements and Cognitive Function During Hypoglycemia and Recovery
Blood/Interstitial Glucose Measurements and Cognitive Function During Hypoglycemia and Recovery
Status: Enrolling
Updated:  9/20/2014
Joslin Diabetes Center
643
mi
from 43215
Boston, MA
Blood/Interstitial Glucose Measurements and Cognitive Function During Hypoglycemia and Recovery
Blood/Interstitial Glucose Measurements and Cognitive Function During Hypoglycemia and Recovery
Status: Enrolling
Updated: 9/20/2014
Joslin Diabetes Center
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study
A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study
Status: Enrolling
Updated:  12/10/2014
Washington University School of Medicine/St. Louis Children's Hospital
397
mi
from 43215
St. Louis, MO
A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study
A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study
Status: Enrolling
Updated: 12/10/2014
Washington University School of Medicine/St. Louis Children's Hospital
397
mi
from 43215
St. Louis, MO
Click here to add this to my saved trials